港股药品股短线拉升，石药集团(01093.HK)涨超11%，泰凌医药(01011.HK)涨超4%，石四药集团 (02005.HK)涨超3%，翰森制药(03692.HK)涨超2%。 ...

Financial Performance - The overall revenue for the year ended December 31, 2024, increased by RMB 30.6 million or 413.5% to RMB 38.0 million compared to RMB 7.4 million in the previous year[8]. - The net loss for the year ended December 31, 2024, was RMB 53.4 million, a decrease of 62.8% from a net loss of RMB 143.6 million in the same period of 2023[8]. - Revenue from digital services and sales agency fees increased by RMB 30.6 million or 413.5% to RMB 38.0 million, primarily due to the new digital services segment starting in 2024[16]. - The cost of sales for the year ending December 31, 2024, was approximately RMB 32.7 million, resulting in a gross profit of about RMB 5.3 million, a decrease of approximately RMB 2.1 million or 28.4% compared to the previous year[17]. - The total comprehensive loss attributable to owners of the company from continuing operations was RMB 53.4 million, compared to RMB 33.5 million in the previous year, with basic and diluted loss per share at RMB 20.20[20]. - Total debt as of December 31, 2024, was RMB 552.96 million, up from RMB 515.66 million in 2023, with a net debt of RMB 543.34 million[25]. - The debt-to-asset ratio increased to 165.52% in 2024 from 156.68% in 2023, indicating a higher leverage position[30]. - The company recorded a net loss from continuing operations of approximately RMB 53.4 million for the year ended December 31, 2024, compared to a net loss of approximately RMB 33.5 million in the previous year[12]. Business Model and Strategy - The company has transitioned from a heavy asset business model to a light asset model, focusing on cost control and improving financial conditions[12]. - The company plans to launch its "AI + Medical Industry" transformation in 2025, establishing new departments in China to support comprehensive medical services[13]. - The company has successfully created the "Faimeng - Smart Medical Health Management" brand, establishing a unique position in the market as the only provider of a complete smart health management ecosystem[7]. - The company aims to develop a comprehensive health platform focusing on orthopedic diseases, including drug supply, rehabilitation management, and digital medical services[11]. - The company is leveraging artificial intelligence to create personalized medical solutions to meet the growing patient demand[13]. - The company has transformed into a light-asset operation focusing on "AI + healthcare," with major business segments including OEM production, agency sales of medical products, and digital healthcare services[14]. Corporate Governance - The board consists of two executive directors, two non-executive directors, and three independent non-executive directors, with independent non-executive directors making up 43% of the board[45]. - The company has adopted the corporate governance code as per the Hong Kong Stock Exchange listing rules and has complied with all applicable provisions for the year ending December 31, 2024, except for the separation of roles between the chairman and CEO[64]. - The board has established procedures to ensure that the selection and nomination of board candidates consider a wide range of backgrounds and experiences[73]. - The board of directors held four regular meetings in 2023, with a 100% attendance rate for all members[78]. - The audit committee reviewed the group's internal controls, risk management, and financial reporting, including the annual results for the year ending December 31, 2023[87]. - The company has received annual confirmations of independence from all current independent non-executive directors, affirming their ability to make independent judgments[67]. Employee and Labor Practices - The total number of full-time employees increased to 22 as of December 31, 2024, compared to 16 in 2023[43]. - Total compensation, benefits, and social security costs amounted to RMB 6.1 million for the year ended December 31, 2024, up from RMB 3.6 million in 2023[43]. - Employee turnover rate for the fiscal year 2024 is 9.09%, down from 12.5% in 2023, with 2 employees leaving in both years[167]. - The company adheres to a comprehensive compensation system, ensuring fair and reasonable salaries and rewards for employees[161]. - The company has a strict policy against discrimination in hiring, compensation, training, and promotion based on race, religion, gender, and other factors[162]. - The company emphasizes employee health and safety, implementing policies to prevent occupational hazards and risks[170]. Environmental, Social, and Governance (ESG) Initiatives - The environmental, social, and governance (ESG) report outlines the company's initiatives and performance for the fiscal year ending December 31, 2024[128]. - The ESG report includes a commitment to sustainable development and highlights the importance of stakeholder engagement in identifying significant issues[135]. - The company plans to expand its ESG reporting scope to include offices in Hainan and Beijing for the 2024 report[129]. - The company has established a governance framework to integrate sustainability principles into daily management and operations[133]. - The company emphasizes the importance of stakeholder feedback in its sustainability efforts, addressing concerns related to product quality and environmental management[135]. - The company has implemented measures to reduce energy consumption, including shutting down idle appliances and replacing old equipment with more energy-efficient models[150]. Financial Management and Liquidity - The company is actively negotiating to obtain new financing sources to repay overdue borrowings[53]. - The board believes that the company will have sufficient operating funds to meet financial obligations due in the next 12 months[52]. - The company has not purchased, sold, or redeemed any of its listed securities during the year ended December 31, 2024[44]. - The company has adopted a dividend policy to maintain sufficient cash reserves for operational needs and future business growth[123]. - The company is preparing to launch an AI-based bone density detection product in 2025, expanding its product offerings in the healthcare sector[14]. Risk Management - The company faces significant uncertainties regarding its ability to continue as a going concern due to various factors, including the need for new financing sources[114]. - The board is responsible for maintaining an effective risk management and internal control system, which is reviewed annually[101]. - The company has established a code of conduct to define ethical standards for all employees[101]. - The company is engaged in a competitive market environment, which may lead to decreased sales, price reductions, and loss of market share[106]. Community Engagement and Corporate Social Responsibility - The company emphasizes community investment, encouraging employees to participate in charitable activities and fundraising initiatives[191]. - The company is committed to corporate social responsibility, actively participating in community activities to foster a positive corporate culture[191]. - The company plans to enhance its community engagement efforts to further contribute to societal well-being[191].

港股泰凌医药(01011.HK)跌超25%，总市值达2.9亿港元。 ...

港股泰凌医药午后跌近26%，早盘一度涨超31%。 ...

港股创新药板块盘初走高，泰凌医药涨近7%，石药集团涨超4%，百济神州、昭衍新药（603127）、药 明生物纷纷上涨。 ...

港股泰凌医药(01011.HK)涨近14%，公司发新股收购人工智能医疗业务，涉资1.2亿元。 ...

全年業績 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於開曼群島註冊成立之有限公司） （股份代號：1011） 截 至2024 年12 月31 日止年度經審核全年業績公告 中 國 泰 凌 醫 藥 集 團 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至2024年12月31日止年度的經審核綜合業 績，以 及 上 一 年 的 比 較 數 字，其 已 根 據 香 港 財 務 報 告 準 則（「香港財務報告準則」） 編 製，並 經 本 公 司 審 核 委 員 會 審 閱 如 下。 – 1 – 綜合損益及其他全面收益表 截 至2024 年12 月31 日止年度 | | | | | | | | | | | | 2024 年 | 2023 年 | | | --- | --- | --- | --- | --- | ...

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of RMB 31,297,000, compared to RMB 25,591,000 for the same period in 2023, representing a year-over-year increase of 22%[3] - The gross profit for the same period was RMB 5,706,000, down from RMB 7,366,000 in 2023, indicating a decrease of approximately 22.5%[3] - The company achieved a profit before tax of RMB 785,000, a significant improvement from a loss of RMB 4,796,000 in the previous year[3] - The net profit attributable to the owners of the company for the period was RMB 661,000, compared to a loss of RMB 5,612,000 in the same period last year[3] - The company reported a total comprehensive loss of RMB 6,850,000 for the period, compared to a loss of RMB 10,137,000 in the previous year, showing a reduction in losses of about 32%[4] - The company reported a pre-tax loss of RMB 661,000 for the six months ended June 30, 2024, compared to a loss of RMB 4,796,000 for the same period in 2023, indicating a significant improvement[19] - The company's profit attributable to equity holders from continuing operations was approximately RMB 0.7 million, compared to a loss of RMB 4.8 million in the same period last year[42] Assets and Liabilities - The total assets as of June 30, 2024, were RMB 14,404,000, an increase from RMB 12,277,000 as of December 31, 2023[5] - The company's current liabilities increased to RMB 681,615,000 from RMB 665,087,000 at the end of 2023, reflecting a rise of approximately 2.4%[6] - As of June 30, 2024, the group's current liabilities amounted to approximately RMB 667,211,000, and total borrowings were approximately RMB 356,133,000[9] - The company's total bank and other borrowings amounted to RMB 352,878,000, an increase from RMB 340,708,000 as of December 31, 2023, representing a growth of approximately 3.43%[25] - Total debt as of June 30, 2024, was RMB 527.3 million, compared to RMB 515.7 million as of December 31, 2023, with a debt-to-asset ratio of 155.7%[50] - The net debt amount was RMB 521.5 million as of June 30, 2024, compared to RMB 514.1 million as of December 31, 2023[46] Cash Flow and Liquidity - Cash and bank balances rose significantly to RMB 5,791,000 from RMB 1,520,000, indicating a substantial improvement in liquidity[5] - The group reported a cash and bank balance of approximately RMB 5,791,000 as of June 30, 2024[9] - The company is exploring new financing sources or strategic capital investments to improve its cash flow situation[10] - Financing costs decreased by approximately RMB 7.1 million or 54.2% to about RMB 6.0 million compared to RMB 13.1 million in the same period last year, primarily due to a reduction in borrowings[41] Operational Developments - The company continues to focus on research and development in the pharmaceutical sector, aiming to enhance its product offerings and market presence[7] - The group aims to develop a comprehensive platform enterprise covering the entire management of orthopedic treatment[10] - The company has established four platforms: pharmaceutical sales service platform, cross-border health platform, medical device promotion platform, and medical digital service platform, all set to launch between 2024 and 2025[35] - The company has acquired a patent for a specialized orthopedic pain treatment drug, expected to be registered and launched for sale in 2024[36] - The company plans to leverage artificial intelligence to build a multi-supply bridge in the bone health sector, integrating medical equipment and rehabilitation services[35] Customer and Revenue Insights - Revenue from digital services and sales agency fees increased to RMB 31,297,000 for the six months ended June 30, 2024, compared to RMB 7,366,000 in the same period of 2023[12] - Major customer B contributed RMB 30,793,000 to total group revenue for the six months ended June 30, 2024, while major customer A contributed RMB 7,366,000 in the previous year[13] Cost Management - The company has taken measures to control administrative costs through human resource optimization and capital expenditure control[10] - The total sales cost for Suzhou First Pharmaceutical was RMB 75,243,000, leading to a gross profit of RMB 44,937,000 for the six months ended June 30, 2023[31] - The company has allocated HKD 2,000,000 for processing fees related to orthopedic drug production, with expected utilization by December 2024[54] Corporate Governance and Compliance - The financial statements were prepared in accordance with the Hong Kong Financial Reporting Standards, ensuring compliance and transparency[8] - The company has adhered to all applicable corporate governance codes as of June 30, 2024, except for the separation of roles between the Chairman and CEO, which is currently held by the same individual[58] - The audit committee is composed entirely of independent non-executive directors, ensuring independence in oversight[61] Employee and Compensation - As of June 30, 2024, the total cost for employee compensation, benefits, and social security was approximately RMB 2.5 million, compared to RMB 1.0 million for the same period in 2023[56] - The group employed 20 full-time employees as of June 30, 2024, an increase from 9 employees a year earlier[56] Future Outlook - The company aims to become the largest provider of digital medical information services in the bone health sector in China[37] - The aging population in China is projected to reach 35% by 2060, indicating significant market potential for osteoporosis treatments[35] Dividends and Shareholder Information - The company did not declare or pay any dividends for the six months ended June 30, 2024, consistent with the previous year[33] - No interim dividend has been recommended for the six months ended June 30, 2024, compared to no dividend in 2023[60] - The company will issue its interim report by September 30, 2024, or earlier, to shareholders[63]

Product Development and Launch - The company has acquired a pain relief medication for orthopedic treatment, expected to launch in 2024[4] - The company is currently representing two osteoporosis treatment medications, with one service contract signed and promotion underway[4] - A new orthopedic health brand will be launched this year to enhance market penetration and brand value[4] - A total of HKD 1,500,000 is allocated for the development of bone health products, with one R&D project requiring HKD 2,900,000 expected to be utilized by the end of 2026[12] Business Expansion - The company has established new subsidiaries in Hainan and Beijing to expand its business operations[8] - The company has established a cross-border health platform with three proprietary products and over ten international brands, currently selling on major e-commerce platforms[18] - The company is focusing on the orthopedic health sector, leveraging national policies to create new value for shareholders[8] Partnerships and Collaborations - The company has partnered with a data-driven AI diagnostic company to promote osteoporosis diagnostic equipment and services in the Asia-Pacific region[10] - The company holds a 25.3% stake in Beijing Kangchen Biotechnology Co., continuing investment in A-share listed enterprises[17] Financial Management - The company plans to utilize HKD 2,000,000 for processing fees related to orthopedic drug production by the end of 2024[12] - On September 21, 2023, the company completed a placement of 263,073,000 new shares at a price of HKD 0.05 per share, raising approximately HKD 12 million after expenses[21] - The board has no intention to change the planned use of the net proceeds from the placement as of the report date[23] - The expected timeline for utilizing the net proceeds is based on the company's best estimates and may change according to market conditions[23] Service Provision and Market Position - The company aims to establish the largest digital medical information service provider in the bone health sector in the country[19] - As of the first half of 2024, the company has already provided services to one enterprise and is gradually expanding its user base[19]

發 重 新 目錄 2 公司資料 4 主席報告 5 管理層討論及分析 16 董事履歷詳情 19 企業管治報告 38 環境、社會及管治報告 69 董事會報告 79 獨立核數師報告 82 綜合損益及其他全面收益表 84 綜合財務狀況表 86 綜合權益變動表 87 綜合現金流量表 89 綜合財務報表附註 190 五年財務概要 公司資料 | 董事會 | | | --- | --- | | 執行董事 | 吳鐵先生 （主席兼行政總裁） | | | 吳靜美女士（於2024年1月15日獲委任） | | 非執行董事 | 錢唯博士 | | | 錢余女士（於2024年1月15日由執行董事調任為非執行董事） | | 獨立非執行董事 | 余梓山先生 | | | 趙玉彪博士 | | | 吳銘軍先生（於2023年1月19日獲委任） | | | 潘飛先生（於2023年1月19日辭任） | | 董事委員會 | | | 審核委員會 | 吳銘軍先生 （主席） | | | 余梓山先生 | | | 趙玉彪博士 | | 薪酬委員會 | 余梓山先生 （主席） | | | 吳鐵先生 | | | 趙玉彪博士 | | 提名委員會 | 吳鐵先生 （主席） | | ...